Introduction {#sec1_1}
============

Dermatomyositis (DM) is an idiopathic inflammatory myositis characterized by muscle pain, muscle weakness, and skin rash \[[@B1]\]. DM is often concomitant with malignant tumors such as gastric cancer, lung cancer, malignant lymphoma, ovarian carcinoma, breast cancer, and colorectal cancer. Concomitant occurrence with intrahepatic cholangiocarcinoma (ICC) is extremely rare \[[@B2]\]. We herein report a successful treated case of ICC which was detected during exacerbation of DM.

Case Presentation {#sec1_2}
=================

A 44-year-old female had been suffering from dry cough, myalgia, and arthralgia since 2013 and was diagnosed as DM (Table [1](#T1){ref-type="table"}). Her symptoms were abated by combination treatment using prednisolone and tacrolimus. However, the cough, pyrexia, and arthralgia recurred due to the exacerbation of DM. The patient was admitted to our hospital for further checkup and treatment. Laboratory data showed that her white blood cell count and C-reactive protein levels were elevated. Her serum carcinoembryonic antigen and carbohydrate antigen 19-9 were not elevated (Table [2](#T2){ref-type="table"}). Enhanced computed tomography showed a 20-mm low-density tumor with a gradual enhancement in segment 4 of the liver (Fig. [1a](#F1){ref-type="fig"}). Ultrasonography showed a 20-mm tumor in segment 4 of the liver (Fig. [1b](#F1){ref-type="fig"}). In magnetic resonance imaging (MRI), the tumor had a weak signal intensity on T1-weighted images and a strong signal intensity on T2-weighted and diffusion-weighted images. In the dynamic study of MRI, enhancement of the edge of the tumor was gradually increased from the early to the late phase (Fig. [1c](#F1){ref-type="fig"}). Following the diagnosis of ICC in segment 4 of the liver, hepatic medial segmentectomy and cholecystectomy were performed. In the resected specimen, macroscopic findings consisted of a solid hepatic tumor with the diameter of 35 × 25 × 21 mm (Fig. [2](#F2){ref-type="fig"}). The pathological diagnosis was moderately differentiated adenocarcinoma with vascular invasions and without lymph node metastasis (pStage III). The tumor consists of cells with coarse chromatin (Fig. [3](#F3){ref-type="fig"}). Many of the tumors have tube formation and immunohistological findings of intrahepatic ICC and moderately differentiated adenocarcinoma with CK7 (+), CK 19 (+), and CK 20 (--) (Fig. [4](#F4){ref-type="fig"}). The patient made a satisfactory recovery with no postoperative complications and was transferred to the Department of the Internal Medicine to treat DM with tacrolimus 5 mg/day and prednisone 20 mg/day. The patient was discharged on postoperative day 23. Since this case was a high-risk case of stage III with vascular invasion, adjuvant chemotherapy using S-1 for 6 months was performed. The patient has remained well without recurrence of ICC or relapse of DM after hepatic resection.

Discussion {#sec1_3}
==========

The incidence of concomitant malignant tumors in patients with DM is quite high, ranging from 15 to 32% \[[@B2], [@B3]\], and significantly higher than those in people without DM. The relative risk of cancer was 2.4 (95% confidence interval, 1.6--3.6) in the male patients and 3.4 (95% confidence interval, 2.4--4.7) in the female patients \[[@B3]\]. Among Japanese patients, the frequent concomitant malignant tumors with DM consist of gastric, lung, uterine, breast, and liver cancers \[[@B4], [@B5]\]. Concomitance of ICC with DM is extremely rare.

Genetic changes caused by a viral infection or changes in the immune system such as an antigen-antibody reaction of DM may be one of the possible mechanisms of the association between DM and the development of malignant tumors \[[@B6], [@B7]\]. However, the detailed mechanisms are still unclear. There have been reported cases of malignant tumors, which were detected with the exacerbation of DM and with the improvement of the symptoms of DM after treatment of the malignant tumor \[[@B3]\]. One-third of the DM patients with malignant tumors are cured by treatment, including resection of the tumor \[[@B8]\]. We herein reported a successfully treated case of ICC by hepatic resection and adjuvant chemotherapy, which was detected with the exacerbation of DM. In the present case, the symptoms of DM improved after treatment of ICC. This case was suspected to have paraneoplastic syndrome, which was discovered due to the exacerbation of DM that was caused by the intrahepatic ICC. When these symptoms worsened, a systemic scan for malignant tumors was believed to be necessary.
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![Image findings. **a** Computed tomography showing a 20-mm low-density tumor with gradual enhancement in segment 4 of the liver. **b** Ultrasonography showing a 20-mm tumor in segment 4 of the liver. **c** In the dynamic study of MRI, enhancement of the edge of the tumor gradually increased from the early to the late phase.](crg-0012-0622-g01){#F1}

![Macroscopic findings. Macroscopic findings of a solid hepatic tumor with the diameter of 35 × 25 × 21 mm.](crg-0012-0622-g02){#F2}

![Microscopic findings (HE staining). The tumor consists of cells with coarse chromatin.](crg-0012-0622-g03){#F3}

![Microscopic findings. Immunohistological findings of intrahepatic ICC and moderately differentiated adenocarcinoma with CK7 (+), CK 19 (+), and CK 20 (--).](crg-0012-0622-g04){#F4}

###### 

Laboratory data before treatment for DM

  ---------- ------------- -------------- ------------
  RF         3.8 IU/mL     ANA(IF)        negative
  IgG        1,675 mg/dL   Anti-dsDNAAb   \<10 U/mL
  IgA        439 mg/dL     Anti-SmAb      \<7.0 U/mL
  IgM        158 mg/dL     Anti-SS-Aab    \<7.0 U/mL
  C3         74 mg/dL      Anti-RNPAb     \<7.0 U/mL
  C4         13 mg/dL      Anti-Jo-1Ab    \>500 U/mL
  CH50       35.9 mg/dL    Anti-Scl70Ab   \<7.0 U/mL
  MMP-3      98.3 ng/mL    C-ANCA         \<1.0 U/mL
  Anti-CCP   \<0.6 U/mL    P-ANCA         \<1.0 U/mL
                           Anti-TIFIAb    negative
  ---------- ------------- -------------- ------------

Elevations other than anti-Jo-1Ab were not observed.

###### 

Laboratory data before the operation

  -------- ----------------- ------- ------------ ---------- -----------
  WBC      19,900/µl         AST     28 IU/L      TC         263 mg/dL
  RBC      3.88 × 10^6^/µL   ALT     22 IU/L      TG         113 mg/dL
  Hb       12.0 g/dL         LDH     362 IU/L     HbA1C      6.1%
  Ht       37.8%             ChE     195 IU/L                
  Plt      377 × 10^3^/µL    T-Bil   0.7 mg/dL               
                             D-Bil   0.1 mg/dL               
                             ALP     238 IU/l     HBs Ag     negative
                             γ-GTP   32 IU/l      HCVAb      positive
                             TP      6.7 g/dL     HCV-RNA    negative
  PT       090%              Alb     2.8 g/dL                
  PT-INR   1.0               UN      8 mg/dL                 
  APTT     31.9 s            Cr      0.55 mg/dL   CEA        1.2 ng/mL
  Fbg      576 mg/dL         UA      3.8 mg/dL    CA19-9     8 ng/mL
                             Na      139 mEq/L    AFP        2 ng/mL
                             K       3.8 mEq/L    PIVKA-II   17 mAu/mL
                             Cl      102 mEq/L    ICG(R15)   8%
                             CRP     7.7 mg/dL    LHL15      0.964
  -------- ----------------- ------- ------------ ---------- -----------
